Skip to main content
Erschienen in: World Journal of Surgery 11/2021

02.08.2021 | Original Scientific Report

Impact of Tumor Burden Score on Conditional Survival after Curative-Intent Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis

verfasst von: Ahmed N. Elfadaly, Diamantis I. Tsilimigras, J. Madison Hyer, Alessandro Paro, Fabio Bagante, Francesca Ratti, Hugo P. Marques, Olivier Soubrane, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Tom Hugh, Luca Aldrighetti, Itaru Endo, Timothy M. Pawlik

Erschienen in: World Journal of Surgery | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of tumor burden score (TBS) on conditional survival (CS) among patients undergoing curative-intent resection of hepatocellular carcinoma (HCC) has not been examined to date.

Methods

Patients who underwent liver resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS and other clinicopathologic factors on 3-year conditional survival (CS3) was examined.

Results

Among 1,040 patients, 263 (25.3%) patients had low TBS, 668 (64.2%) had medium TBS and 109 (10.5%) had high TBS. TBS was strongly associated with OS; 5-year OS was 39.0% among patients with high TBS compared with 61.1% and 79.4% among patients with medium and low TBS, respectively (p < 0.001). While actuarial survival decreased as time elapsed from resection, CS increased over time irrespective of TBS. The largest differences between 3-year actuarial survival and CS3 were noted among patients with high TBS (5-years postoperatively; CS3: 78.7% vs. 3-year actuarial survival: 30.7%). The effect of adverse clinicopathologic factors including high TBS, poor/undifferentiated tumor grade, microvascular invasion, liver capsule involvement, and positive margins on prognosis decreased over time.

Conclusions

CS rates among patients who underwent resection for HCC increased as patients survived additional years, irrespective of TBS. CS estimates can be used to provide important dynamic information relative to the changing survival probability after resection of HCC.
Literatur
1.
Zurück zum Zitat Jemal A, Ward EM, Johnson CJ, et al (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst 109 Jemal A, Ward EM, Johnson CJ, et al (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst 109
2.
Zurück zum Zitat Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477–491CrossRef Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477–491CrossRef
3.
Zurück zum Zitat White DL, Thrift AP, Kanwal F et al (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 152:812–820CrossRef White DL, Thrift AP, Kanwal F et al (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 152:812–820CrossRef
4.
Zurück zum Zitat Tsilimigras DI, Bagante F, Moris D et al (2019) Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer guidelines: a multi-institutional analysis of 1010 patients. Surgery 166:967–974CrossRef Tsilimigras DI, Bagante F, Moris D et al (2019) Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer guidelines: a multi-institutional analysis of 1010 patients. Surgery 166:967–974CrossRef
5.
Zurück zum Zitat Pinna AD, Yang T, Mazzaferro V et al (2018) Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 268:868–875CrossRef Pinna AD, Yang T, Mazzaferro V et al (2018) Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg 268:868–875CrossRef
6.
Zurück zum Zitat European Association for the Study of the Liver (2018) Electronic address eee, european association for the study of the L EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef European Association for the Study of the Liver (2018) Electronic address eee, european association for the study of the L EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef
7.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: A Cancer J Clin. 67:93-99 Amin MB, Greene FL, Edge SB, et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: A Cancer J Clin. 67:93-99
8.
Zurück zum Zitat Tsilimigras DI, Moris D, Hyer JM et al (2020) Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 107:854–864CrossRef Tsilimigras DI, Moris D, Hyer JM et al (2020) Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 107:854–864CrossRef
9.
Zurück zum Zitat Shah MM, Meyer BI, Rhee K et al (2020) Conditional survival analysis of hepatocellular carcinoma. J Surg Oncol 122(4):684–690CrossRef Shah MM, Meyer BI, Rhee K et al (2020) Conditional survival analysis of hepatocellular carcinoma. J Surg Oncol 122(4):684–690CrossRef
10.
Zurück zum Zitat Kurta ML, Edwards RP, Moysich KB et al (2014) Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol 32:4102–4112CrossRef Kurta ML, Edwards RP, Moysich KB et al (2014) Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol 32:4102–4112CrossRef
11.
Zurück zum Zitat Spolverato G, Kim Y, Ejaz A et al (2015) Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg 150:538–545CrossRef Spolverato G, Kim Y, Ejaz A et al (2015) Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg 150:538–545CrossRef
12.
Zurück zum Zitat Hieke S, Kleber M, Konig C et al (2015) Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res 21:1530–1536CrossRef Hieke S, Kleber M, Konig C et al (2015) Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res 21:1530–1536CrossRef
13.
Zurück zum Zitat Park YK, Song SK, Kim BW et al (2017) Conditional survival analysis demonstrates that recurrence risk of surgically treated hepatocellular carcinoma evolves with time. J Gastrointest Surg 21:1237–1244CrossRef Park YK, Song SK, Kim BW et al (2017) Conditional survival analysis demonstrates that recurrence risk of surgically treated hepatocellular carcinoma evolves with time. J Gastrointest Surg 21:1237–1244CrossRef
14.
Zurück zum Zitat Cucchetti A, Piscaglia F, Cescon M et al (2012) Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res 18:4397–4405CrossRef Cucchetti A, Piscaglia F, Cescon M et al (2012) Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res 18:4397–4405CrossRef
15.
Zurück zum Zitat Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132–141CrossRef Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132–141CrossRef
16.
Zurück zum Zitat Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355CrossRef Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355CrossRef
17.
Zurück zum Zitat Buettner S, Margonis GA, Kim Y et al (2016) Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford) 18:510–517CrossRef Buettner S, Margonis GA, Kim Y et al (2016) Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford) 18:510–517CrossRef
18.
Zurück zum Zitat Beal EW, Tumin D, Kabir A et al (2017) Trends in the mortality of hepatocellular carcinoma in the United States. J Gastrointest Surg 21:2033–2038CrossRef Beal EW, Tumin D, Kabir A et al (2017) Trends in the mortality of hepatocellular carcinoma in the United States. J Gastrointest Surg 21:2033–2038CrossRef
19.
Zurück zum Zitat Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24:1–17CrossRef Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24:1–17CrossRef
20.
Zurück zum Zitat Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20-37CrossRef Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20-37CrossRef
21.
Zurück zum Zitat Yu SJ (2016) A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 22:7–17CrossRef Yu SJ (2016) A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 22:7–17CrossRef
22.
Zurück zum Zitat Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRef Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRef
23.
Zurück zum Zitat Kim Y, Ejaz A, Spolverato G et al (2015) Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. Ann Surg Oncol 22:557–564CrossRef Kim Y, Ejaz A, Spolverato G et al (2015) Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. Ann Surg Oncol 22:557–564CrossRef
24.
Zurück zum Zitat Henson DE, Ries LA (1994) On the estimation of survival. Semin Surg Oncol 10:2–6CrossRef Henson DE, Ries LA (1994) On the estimation of survival. Semin Surg Oncol 10:2–6CrossRef
25.
Zurück zum Zitat Zabor EC, Gonen M, Chapman PB et al (2013) Dynamic prognostication using conditional survival estimates. Cancer 119:3589–3592CrossRef Zabor EC, Gonen M, Chapman PB et al (2013) Dynamic prognostication using conditional survival estimates. Cancer 119:3589–3592CrossRef
26.
Zurück zum Zitat Tsilimigras DI, Mehta R, Paredes AZ et al (2020) overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg 272:574–581CrossRef Tsilimigras DI, Mehta R, Paredes AZ et al (2020) overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg 272:574–581CrossRef
27.
Zurück zum Zitat Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the barcelona clinic liver cancer staging system. J Hepatol 44:723–731CrossRef Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the barcelona clinic liver cancer staging system. J Hepatol 44:723–731CrossRef
28.
Zurück zum Zitat Zamboni BA, Yothers G, Choi M et al (2010) Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 28:2544–2548CrossRef Zamboni BA, Yothers G, Choi M et al (2010) Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 28:2544–2548CrossRef
29.
Zurück zum Zitat Mayo SC, Nathan H, Cameron JL et al (2012) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118:2674–2681CrossRef Mayo SC, Nathan H, Cameron JL et al (2012) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118:2674–2681CrossRef
30.
Zurück zum Zitat Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721CrossRef Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721CrossRef
31.
Zurück zum Zitat Wang J, He XD, Yao N et al (2013) A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 27:351–363CrossRef Wang J, He XD, Yao N et al (2013) A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 27:351–363CrossRef
32.
Zurück zum Zitat Yamamoto M, Arii S, Sugahara K et al (1996) Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83:336–340CrossRef Yamamoto M, Arii S, Sugahara K et al (1996) Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83:336–340CrossRef
33.
Zurück zum Zitat Takayama T, Sekine T, Makuuchi M et al (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807CrossRef Takayama T, Sekine T, Makuuchi M et al (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807CrossRef
34.
Zurück zum Zitat Liao M, Zhu Z, Wang H et al (2017) Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 52:624–634CrossRef Liao M, Zhu Z, Wang H et al (2017) Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol 52:624–634CrossRef
35.
Zurück zum Zitat Qi X, Liu L, Wang D et al (2015) Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 6:36838–36859CrossRef Qi X, Liu L, Wang D et al (2015) Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 6:36838–36859CrossRef
36.
Zurück zum Zitat Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422CrossRef Cucchetti A, Piscaglia F, Caturelli E et al (2009) Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 16:413–422CrossRef
Metadaten
Titel
Impact of Tumor Burden Score on Conditional Survival after Curative-Intent Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis
verfasst von
Ahmed N. Elfadaly
Diamantis I. Tsilimigras
J. Madison Hyer
Alessandro Paro
Fabio Bagante
Francesca Ratti
Hugo P. Marques
Olivier Soubrane
Vincent Lam
George A. Poultsides
Irinel Popescu
Sorin Alexandrescu
Guillaume Martel
Aklile Workneh
Alfredo Guglielmi
Tom Hugh
Luca Aldrighetti
Itaru Endo
Timothy M. Pawlik
Publikationsdatum
02.08.2021
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 11/2021
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-021-06265-3

Weitere Artikel der Ausgabe 11/2021

World Journal of Surgery 11/2021 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.